Fixed-combination topical anti-hypertensive ophthalmic agents

References

• Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol. 2002;120(10):1268–1279.
   PubMed Web of Science ®Google Scholar
• Gordon MO, Kass MA. What we have learned from the ocular hypertension treatment study. Am J Ophthalmol. 2018;189:xxiv–xxvii.
   PubMed Web of Science ®Google Scholar
• Hollo G, Topouzis F, Fechtner RD. Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice. Expert Opin Pharmacother. 2014;15(12):1737–1747.
   PubMed Web of Science ®Google Scholar
• Collaborative Normal-Tension Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126(4):498–505.
   PubMed Web of Science ®Google Scholar
• Leske MC. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121(1):48–56.
   PubMedGoogle Scholar
• Atey TM, Shibeshi W, Giorgis A, et al. The impact of adherence and instillation proficiency of topical glaucoma medications on intraocular pressure. J Ophthalmol. 2017;2017:1683430.
   PubMed Web of Science ®Google Scholar
• Konstas AG, Hollo G, Haidich AB, et al. Comparison of 24-hour intraocular pressure reduction obtained with brinzolamide/timolol or brimonidine/timolol fixed-combination adjunctive to travoprost therapy. J Ocular Pharmacol Therapeut. 2013;29(7):652–657.
   PubMed Web of Science ®Google Scholar
• Guven Yilmaz S, Degirmenci C, Karakoyun YE, et al. The efficacy and safety of bimatoprost/timolol maleate, latanoprost/timolol maleate, and travoprost/timolol maleate fixed combinations on 24-h IOP. Int Ophthalmol. 2018;38(4):1425–1431.
   PubMed Web of Science ®Google Scholar
• Higginbotham EJ, Hansen J, Davis EJ, et al. Glaucoma medication persistence with a fixed combination versus multiple bottles. Curr Med Res Opin. 2009;25(10):2543–2547.
   PubMed Web of Science ®Google Scholar
• Hommer A, Thygesen J, Ferreras A, et al. A European perspective on costs and cost effectiveness of ophthalmic combinations in the treatment of open-angle glaucoma. Eur J Ophthalmol. 2008;18(5):778–786.
   PubMed Web of Science ®Google Scholar
• Moosavi R, Ansari E. Brinzolamide/brimonidine fixed combination: simplifying glaucoma treatment regimens. Ophthalmol Ther. 2018;7(2):397–403.
   PubMed Web of Science ®Google Scholar
• Hasebe Y, Kashiwagi K, Tsumura T, et al. Changes in adherence and associated factors among patients on newly introduced prostaglandin analog and timolol fixed-combination therapy. Patient Prefer Adherence. 2018;12:1567–1577.
   PubMed Web of Science ®Google Scholar
• Tsumura T, Kashiwagi K, Suzuki Y, et al. A nationwide survey of factors influencing adherence to ocular hypotensive eyedrops in Japan. Int Ophthalmol. 2019;39(2):375–383.
   PubMed Web of Science ®Google Scholar
• Gurwitz JH, Glynn RJ, Monane M, et al. Treatment for glaucoma: adherence by the elderly. Am J Public Health. 1993;83(5):711–716.
   PubMed Web of Science ®Google Scholar
• Negri L, Ferreras A, Iester M. Timolol 0.1% in glaucomatous patients: efficacy, tolerance, and quality of life. J Ophthalmol. 2019;2019:4146124.
   PubMed Web of Science ®Google Scholar
• Razeghinejad MR, Sawchyn AK, Katz LJ. Fixed combinations of dorzolamide-timolol and brimonidine-timolol in the management of glaucoma. Expert Opin Pharmacother. 2010;11(6):959–968.
   PubMed Web of Science ®Google Scholar
• Schuman JS. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2. Ophthalmology. 2000;107(6):1171–1177.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibitors and activators for novel therapeutic applications. Future Med Chem. 2011;3(9):1165–1180.
   PubMed Web of Science ®Google Scholar
• Iester M. Brinzolamide ophthalmic suspension: a review of its pharmacology and use in the treatment of open angle glaucoma and ocular hypertension. Clin Ophthalmol. 2008;2:517–523.
   PubMedGoogle Scholar
• Ormrod D, McClellan K. Topical dorzolamide 2%/timolol 0.5%: a review of its use in the treatment of open-angle glaucoma. Drugs Aging. 2000;17(6):477–496.
   PubMed Web of Science ®Google Scholar
• Dikopf MS, Vajaranant TS, Edward DP. Topical treatment of glaucoma: established and emerging pharmacology. Expert Opin Pharmacother. 2017;18(9):885–898.
   PubMed Web of Science ®Google Scholar
• Maren TH Carbonic anhydrase inhibition in ophthalmology: aqueous humor secretion and the development of sulfonamide inhibitors. Exs 2000:425–435.
   Google Scholar
• Talluto DM, Wyse TB, Krupin T. Topical carbonic anhydrase inhibitors. Curr Opin Ophthalmol. 1997;8(2):2–6.
   PubMedGoogle Scholar
• Scozzafava A, Supuran CT. Glaucoma and the applications of carbonic anhydrase inhibitors. Subcell Biochem. 2014;75:349–359.
   PubMedGoogle Scholar
• Griggs RC. Use of acetazolamide in sulfonamide-allergic patients with neurologic channelopathies. Arch Neurol. 2012;69(4):527–529.
   PubMedGoogle Scholar
• Lo JS, Pang PM, Lo SC. Efficacy and tolerability of brinzolamide/brimonidine suspension and prostaglandin analogs in patients previously treated with dorzolamide/timolol solution and prostaglandin analogs. Clin Ophthalmol. 2016;10:583–586.
   PubMed Web of Science ®Google Scholar
• Boyle JE, Ghosh K, Gieser DK, et al. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Ophthalmology. 1999;106(12 Suppl):10–16.
   PubMed Web of Science ®Google Scholar
• Kitazawa Y, Araie M. Double-masked, phase III comparative study of the combination ophthalmic solution of the 1% dorzolamide hydrochloride/0.5% timolol maleate (MK-0507A) in patients with glaucoma and ocular hypertension. Nippon Ganka Gakkai Zasshi. 2011;115(6):495–507.
   PubMedGoogle Scholar
• Frampton JE, Perry CM. Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension. Drugs Aging. 2006;23(12):977–995.
   PubMed Web of Science ®Google Scholar
• Hollo G, Bozkurt B, Irkec M. Brinzolamide/timolol fixed combination: a new ocular suspension for the treatment of open-angle glaucoma and ocular hypertension. Expert Opin Pharmacother. 2009;10(12):2015–2024.
   PubMed Web of Science ®Google Scholar
• Silver LH. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide primary therapy study group. Am J Ophthalmol. 1998;126(3):400–408.
   PubMed Web of Science ®Google Scholar
• Iester M. Brinzolamide. Expert Opin Pharmacother. 2008;9(4):653–662.
   PubMed Web of Science ®Google Scholar
• Shin D. Adjunctive therapy with brinzolamide 1% ophthalmic suspension (Azopt) in patients with open-angle glaucoma or ocular hypertension maintained on timolol therapy. Surv Ophthalmol. 2000;44(Suppl 2):S163–8.
   PubMedGoogle Scholar
• Kaback M, Scoper SV, Arzeno G, et al. Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%. Ophthalmology. 2008;115:1728–34,1734 e1–2.
   PubMed Web of Science ®Google Scholar
• Agency EM. Assessment report for Azarga. 2008.
   Google Scholar
• Galose MS, Elsaied HM, Macky TA, et al. Brinzolamide/timolol versus dorzolamide/timolol fixed combinations: A hospital-based, prospective, randomized study. Indian J Ophthalmol. 2016;64(2):127–131.
   PubMed Web of Science ®Google Scholar
• Sezgin Akcay BI, Guney E, Bozkurt KT, et al. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. J Ocular Pharmacol Therapeut. 2013;29(10):882–886.
   PubMed Web of Science ®Google Scholar
• Manni G, Denis P, Chew P, et al. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2009;18(4):293–300.
   PubMed Web of Science ®Google Scholar
• Lanzl I, Raber T. Efficacy and tolerability of the fixed combination of brinzolamide 1% and timolol 0.5% in daily practice. Clin Ophthalmol. 2011;5:291–298.
   PubMedGoogle Scholar
• Sanseau A, Sampaolesi J, Suzuki ER Jr., et al. Preference for a fixed combination of brinzolamide/timolol versus dorzolamide/timolol among patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2013;7:357–362.
   PubMedGoogle Scholar
• Oh DJ, Chen JL, Vajaranant TS, et al. Brimonidine tartrate for the treatment of glaucoma. Expert Opin Pharmacother. 2019;20(1):115–122.
   PubMed Web of Science ®Google Scholar
• Chew SK, Skalicky SE, Goldberg I. Brinzolamide plus brimonidine for the treatment of glaucoma: an update. Expert Opin Pharmacother. 2014;15(16):2461–2471.
   PubMed Web of Science ®Google Scholar
• Adkins JC, Balfour JA. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. Drugs Aging. 1998;12(3):225–241.
   PubMed Web of Science ®Google Scholar
• Cantor LB. Brimonidine in the treatment of glaucoma and ocular hypertension. Ther Clin Risk Manag. 2006;2(4):337–346.
   PubMedGoogle Scholar
• Bhatti A, Singh G. Efficacy of three different formulations of brimonidine for control of intraocular pressure in primary open-angle glaucoma: A 6-week randomized trial. Oman J Ophthalmol. 2018;11(2):140–143.
   PubMedGoogle Scholar
• Dong JQ, Babusis DM, Welty DF, et al. Effects of the preservative purite on the bioavailability of brimonidine in the aqueous humor of rabbits. J Ocular Pharmacol Therapeut. 2004;20(4):285–292.
   PubMed Web of Science ®Google Scholar
• Sethi HS, Naik M, Gupta VS. Management of glaucoma in pregnancy: risks or choices, a dilemma? Int J Ophthalmol. 2016;9(11):1684–1690.
   PubMed Web of Science ®Google Scholar
• Katz G, Dubiner H, Samples J, et al. Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%. JAMA Ophthalmol. 2013;131(6):724–730.
   PubMed Web of Science ®Google Scholar
• Sherwood MB, Craven ER, Chou C, et al., Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol. 2006;124(9): 1230–1238.
   PubMedGoogle Scholar
• Spaeth GL, Bernstein P, Caprioli J, et al. Control of intraocular pressure and fluctuation with fixed-combination brimonidine-timolol versus brimonidine or timolol monotherapy. Am J Ophthalmol. 2011;151(1):93–99 e4.
   PubMed Web of Science ®Google Scholar
• Goni FJ. Brimonidine/Timolol fixed combination study G. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Eur J Ophthalmol. 2005;15:581–590.
   PubMed Web of Science ®Google Scholar
• Motolko MA. Comparison of allergy rates in glaucoma patients receiving brimonidine 0.2% monotherapy versus fixed-combination brimonidine 0.2%-timolol 0.5% therapy. Curr Med Res Opin. 2008;24(9):2663–2667.
   PubMed Web of Science ®Google Scholar
• Alvarado JA. Reduced ocular allergy with fixed-combination 0.2% brimonidine-0.5% timolol. Arch Ophthalmol. 2007;125:717(5):717–718. author reply.
   Google Scholar
• Alezzandrini A, Hubatsch D, Alfaro R. Efficacy and tolerability of fixed-combination brinzolamide/timolol in Latin American patients with open-angle glaucoma or ocular hypertension previously on brimonidine/timolol fixed combination. Adv Ther. 2014;31(9):975–985.
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Bacharach J, Fechtner RD, et al. 24-hour intraocular pressure control with fixed-dose combination brinzolamide 1%/brimonidine 0.2%: A multicenter, randomized trial. Ophthalmology. 2019;126(8):1095–1104.
   PubMed Web of Science ®Google Scholar
• Sharma S, Trikha S, Perera SA, et al. Clinical effectiveness of brinzolamide 1%-brimonidine 0.2% fixed combination for primary open-angle glaucoma and ocular hypertension. Clin Ophthalmol. 2015;9:2201–2207.
   PubMed Web of Science ®Google Scholar
• Gandolfi SA, Lim J, Sanseau AC, et al. Randomized trial of brinzolamide/brimonidine versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertension. Adv Ther. 2014;31(12):1213–1227.
   PubMed Web of Science ®Google Scholar
• Whitson JT, Realini T, Nguyen QH, et al. Six-month results from a Phase III randomized trial of fixed-combination brinzolamide 1% + brimonidine 0.2% versus brinzolamide or brimonidine monotherapy in glaucoma or ocular hypertension. Clin Ophthalmol. 2013;7:1053–1060.
   PubMedGoogle Scholar
• Kozobolis V, Konstantinidis A, Sideroudi H, et al. Efficacy of the travoprost/timolol fixed combination versus the concomitant use of travoprost 0.004% and timolol 0.1% gel formulation. Clin Ophthalmol. 2018;12:2393–2398.
   PubMed Web of Science ®Google Scholar
• Baiza-Duran LM, Llamas-Moreno JF, Ayala-Barajas C. Comparison of timolol 0.5% + brimonidine 0.2% + dorzolamide 2% versus timolol 0.5% + brimonidine 0.2% in a Mexican population with primary open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2012;6:1051–1055.
   PubMedGoogle Scholar
• Garcia-Lopez A, Paczka JA, Jimenez-Roman J, et al. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study. BMC Ophthalmol. 2014;14(1):161.
   PubMedGoogle Scholar
• Baiza-Duran LM, Alvarez-Delgado J, Contreras-Rubio AY, et al. The efficacy and safety of two fixed combinations: timolol-dorzolamide-brimonidine versus timolol-dorzolamide. A prospective, randomized, double-masked, multi-center, 6-month clinical trial. Ann Ophthalmol (Skokie). 2009;41(3–4):174–178.
   PubMedGoogle Scholar
• Angeli A, Supuran CT. Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013–2018). Expert Opin Ther Pat. 2019;29(10):793–803.
   PubMed Web of Science ®Google Scholar
• Lee SS, Almazan A, Decker S, et al. Intraocular pressure effects and mechanism of action of topical versus sustained-release bimatoprost. Transl Vis Sci Technol. 2019;8(1):15.
   PubMed Web of Science ®Google Scholar
• Feldman RM. An evaluation of the fixed-combination of latanoprost and timolol for use in open-angle glaucoma and ocular hypertension. Expert Opin Pharmacother. 2004;5(4):909–921.
   PubMed Web of Science ®Google Scholar
• Boboridis K, Konstas AG, Toumanidou V, et al. A 6-month, observational trial investigating with electronic monitoring the level of adherence and ocular surface health with latanoprost/timolol fixed versus latanoprost and timolol unfixed therapy in glaucoma. Investigate Ophthalmol Visual Sci. 2012;53(14).
   Google Scholar
• Lockington D, Macdonald EC, Stewart P, et al. Free radicals and the pH of topical glaucoma medications: a lifetime of ocular chemical injury? Eye (Lond). 2012;26(5):734–741.
   PubMed Web of Science ®Google Scholar
• Herceg M, Noecker R. Travoprost/timolol fixed combination. Expert Opin Pharmacother. 2008;9(6):1059–1065.
   PubMed Web of Science ®Google Scholar
• Lerner SF, Park KH, Hubatsch DA, et al. Efficacy and tolerability of travoprost 0.004%/timolol 0.5% fixed-dose combination for the treatment of primary open-angle glaucoma or ocular hypertension inadequately controlled with beta-blocker monotherapy. J Ophthalmol. 2017;2017:1917570.
   PubMed Web of Science ®Google Scholar
• Schuman JS, Katz GJ, Lewis RA, et al. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2005;140(2):242–250.
   PubMed Web of Science ®Google Scholar
• Barnebey HS, Robin AL. Adherence to fixed-combination versus unfixed travoprost 0.004%/timolol 0.5% for glaucoma or ocular hypertension: a randomized trial. Am J Ophthalmol. 2017;176:61–69.
   PubMed Web of Science ®Google Scholar
• Konstas AG, Kozobolis VP, Katsimpris IE, et al. Efficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patients. Ophthalmology. 2007;114(4):653–657.
   PubMed Web of Science ®Google Scholar
• Higginbotham EJ, Olander KW, Kim EE, et al., Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study. Arch Ophthalmol. 2010;128(2): 165–172.
   PubMedGoogle Scholar
• Xing Y, Jiang FG, Li T. Fixed combination of latanoprost and timolol vs the individual components for primary open angle glaucoma and ocular hypertension: a systematic review and meta-analysis. Int J Ophthalmol. 2014;7(5):879–890.
   PubMed Web of Science ®Google Scholar
• Ozyol E, Ozyol P. The efficacy of a latanoprost/timolol fixed combination versus latanoprost and timolol gel-forming solution unfixed combination on daytime intraocular pressure. J Glaucoma. 2016;25(2):135–139.
   PubMed Web of Science ®Google Scholar
• Quaranta L, Biagioli E, Riva I, et al. Prostaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysis. J Ocular Pharmacol Therapeut. 2013;29(4):382–389.
   PubMed Web of Science ®Google Scholar
• Pfeiffer N. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefe’s Arch Clin Exp Ophthalmol. 2002;240(11):893–899.
   PubMed Web of Science ®Google Scholar
• Pfeiffer N. European latanoprost fixed combination study G. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefe’s Arch Clin Exp Ophthalmol. 2002;240(11):893–899.
   PubMed Web of Science ®Google Scholar
• Alm A, Grunden JW, Kwok KK. Five-year, multicenter safety study of fixed-combination latanoprost/timolol (Xalacom) for open-angle glaucoma and ocular hypertension. J Glaucoma. 2011;20(4):215–222.
   PubMed Web of Science ®Google Scholar
• Martinez A, Sanchez M. Efficacy and safety of bimatoprost/timolol fixed combination in the treatment of glaucoma or ocular hypertension. Expert Opin Pharmacother. 2008;9(1):137–143.
   PubMed Web of Science ®Google Scholar
• Hommer A. Ganfort investigators group I. A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. Eur J Ophthalmol. 2007;17:53–62.
   PubMed Web of Science ®Google Scholar
• Kiland JA, Gabelt BT, Kaufman PL. Studies on the mechanism of action of timolol and on the effects of suppression and redirection of aqueous flow on outflow facility. Exp Eye Res. 2004;78(3):639–651.
   PubMed Web of Science ®Google Scholar
• Konstas AG, Katsanos A, Athanasopoulos GP, et al. Preservative-free tafluprost/timolol fixed combination: comparative 24-h efficacy administered morning or evening in open-angle glaucoma patients. Expert Opin Pharmacother. 2018;19(18):1981–1988.
   PubMed Web of Science ®Google Scholar
• Konstas AG, Quaranta L, Katsanos A, et al. Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension. Br J Ophthalmol. 2013;97(12):1510–1515.
   PubMed Web of Science ®Google Scholar
• Papadia M, Bagnis A, Scotto R, et al. Tafluprost for glaucoma. Expert Opin Pharmacother. 2011;12(15):2393–2401.
   PubMedGoogle Scholar
• Pfeiffer N, Traverso CE, Lorenz K, et al., A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components. Adv Ther. 2014;31(12): 1228–1246.
   PubMed Web of Science ®Google Scholar
• Hollo G, Vuorinen J, Tuominen J, et al. Fixed-dose combination of tafluprost and timolol in the treatment of open-angle glaucoma and ocular hypertension: comparison with other fixed-combination products. Adv Ther. 2014;31(9):932–944.
   PubMed Web of Science ®Google Scholar
• Soares RR, Razeghinejad MR. Efficacy of the combination of carteolol hydrochloride + latanoprost in the treatment of glaucoma and ocular hypertension. Expert Opin Pharmacother. 2018;19(15):1731–1738.
   PubMed Web of Science ®Google Scholar
• Freedman SF, Freedman NJ, Shields MB, et al. Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level. Am J Ophthalmol. 1993;116(5):600–611.
   PubMed Web of Science ®Google Scholar
• Inoue K, Shiokawa M, Ishida K, et al. Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops. Clin Ophthalmol. 2015;9:619–623.
   PubMed Web of Science ®Google Scholar
• Le Jeunne CL, Hugues FC, Dufier JL, et al. Bronchial and cardiovascular effects of ocular topical B-antagonists in asthmatic subjects: comparison of timolol, carteolol, and metipranolol. J Clin Pharmacol. 1989;29(2):97–101.
   PubMed Web of Science ®Google Scholar
• Diggory P, Cassels-Brown A, Fernandez C. Topical beta-blockade with intrinsic sympathomimetic activity offers no advantage for the respiratory and cardiovascular function of elderly people. Age Ageing. 1996;25(6):424–428.
   PubMed Web of Science ®Google Scholar
• Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin-timolol fixed combinations: a meta-analysis of randomized clinical trials. Eur J Ophthalmol. 2012;22(1):5–18.
   PubMed Web of Science ®Google Scholar
• Topouzis F, Melamed S, Danesh-Meyer H, et al. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. Eur J Ophthalmol. 2007;17:183–190.
   PubMed Web of Science ®Google Scholar
• Schnober D, Hubatsch DA, Scherzer ML. Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy. Clin Ophthalmol. 2015;9:825–832.
   PubMed Web of Science ®Google Scholar
• Bourne RRA, Kaarniranta K, Lorenz K, et al. Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study. BMJ Open. 2019;9(4):e024129.
   PubMed Web of Science ®Google Scholar
• Martinez A, Sanchez M. Bimatoprost/timolol fixed combination vs latanoprost/timolol fixed combination in open-angle glaucoma patients. Eye (Lond). 2009;23(4):810–818.
   PubMed Web of Science ®Google Scholar
• Jothi R, Ismail AM, Senthamarai R, et al. A comparative study on the efficacy, safety, and cost-effectiveness of bimatoprost/timolol and dorzolamide/timolol combinations in glaucoma patients. Indian J Pharmacol. 2010;42(6):362–365.
   PubMed Web of Science ®Google Scholar
• He M, Wang W, Huang W. Efficacy and tolerability of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure: a meta-analysis of randomized controlled trials. PLoS One. 2013;8(12):e83606.
   PubMed Web of Science ®Google Scholar
• Hommer A, Sperl P, Resch H, et al., A double-masked randomized crossover study comparing the effect of latanoprost/timolol and brimonidine/timolol fixed combination on intraocular pressure and ocular blood flow in patients with primary open-angle glaucoma or ocular hypertension. J Ocular Pharmacol Therapeut. 2012;28(6): 569–575.
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Scassellati Sforzolini B, Vittitow J, et al. Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in subjects with open-angle glaucoma or ocular hypertension: the APOLLO study. Ophthalmology. 2016;123(5):965–973.
   PubMed Web of Science ®Google Scholar
• Addis VM, Miller-Ellis E. Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy. Clin Ophthalmol. 2018;12:2649–2657.
   PubMed Web of Science ®Google Scholar
• Medeiros FA, Martin KR, Peace J, et al. Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in open-angle glaucoma or ocular hypertension: the LUNAR study. Am J Ophthalmol. 2016;168:250–259.
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Ong T, Scassellati Sforzolini B, et al. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Br J Ophthalmol. 2015;99(6):738–745.
   PubMed Web of Science ®Google Scholar
• Costagliola C, dell’Omo R, Romano MR, et al. Pharmacotherapy of intraocular pressure: part I. Parasympathomimetic, sympathomimetic and sympatholytics. Expert Opin Pharmacother. 2009;10(16):2663–2677.
   PubMed Web of Science ®Google Scholar
• Beasley H, Fraunfelder FT. Retinal detachments and topical ocular miotics. Ophthalmology. 1979;86(1):95–98.
   PubMed Web of Science ®Google Scholar
• Kaluzny JJ, Szaflik J, Czechowicz-Janicka K, et al. Timolol 0.5%/dorzolamide 2% fixed combination versus timolol 0.5%/pilocarpine 2% fixed combination in primary open-angle glaucoma or ocular hypertensive patients. Acta Ophthalmol Scand. 2003;81(4):349–354.
   PubMedGoogle Scholar
• Puustjarvi TJ, Repo LP. Timolol-pilocarpine fixed-ratio combinations in the treatment of chronic open angle glaucoma. A controlled multicenter study of 48 weeks. Scandinavian Timpilo study group. Arch Ophthalmol. 1992;110:1725–1729.
   PubMedGoogle Scholar
• Soderstrom MB, Wallin O, Granstrom PA, et al. Timolol-pilocarpine combined vs timolol and pilocarpine given separately. Am J Ophthalmol. 1989;107(5):465–470.
   PubMed Web of Science ®Google Scholar
• Hostyn P, Le Rebeller MJ, Trinquand C. Fixed combination of carteolol and pilocarpine eye-drops: a double-blind randomized cross-over trial versus carteolol alone on intra-ocular pressure. The study group. Eur J Ophthalmol. 1996;6(1):17–20.
   PubMedGoogle Scholar
• Bron AM, Garcher CP, Sirbat D, et al. Comparison of two fixed beta-blocker-pilocarpine combinations. The carteolol-pilocarpine study group. Eur J Ophthalmol. 1997;7(4):351–356.
   PubMedGoogle Scholar
• Demailly P, Allaire C, Bron V, et al. Effectiveness and tolerance of beta-blocker/pilocarpine combination eye drops in primary open-angle glaucoma and high intraocular pressure. J Glaucoma. 1995;4(4):235–241.
   PubMedGoogle Scholar
• Ozdemir M, Ozdemir G. Comparison of the intraocular pressure lowering effect of latanoprost and carteolol-pilocarpine combination in newly diagnosed glaucoma. Jpn J Ophthalmol. 2003;47(1):72–76.
   PubMed Web of Science ®Google Scholar
• Asrani S, Robin AL, Serle JB, et al. Netarsudil/Latanoprost fixed-dose combination for elevated intraocular pressure: 3-month data from a randomized phase 3 trial. Am J Ophthalmol; 2019;207:248–257.
   PubMed Web of Science ®Google Scholar
• Schehlein EM, Robin AL. Rho-associated kinase inhibitors: evolving strategies in glaucoma treatment. Drugs. 2019;79(10):1031–1036.
   PubMed Web of Science ®Google Scholar
• Berrino E, Supuran CT. Rho-kinase inhibitors in the management of glaucoma. Expert Opin Ther Pat. 2019;29(10):817–827.
   PubMed Web of Science ®Google Scholar
• Dasso L, Al-Khaled T, Sonty S, et al. Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date. Clin Ophthalmol. 2018;12:1939–1944.
   PubMed Web of Science ®Google Scholar
• Khouri AS, Serle JB, Bacharach J, et al. Once-daily netarsudil versus twice-daily timolol in patients with elevated intraocular pressure: the randomized phase 3 ROCKET-4 study. Am J Ophthalmol. 2019;204:97–104.
   PubMed Web of Science ®Google Scholar
• Lewis RA, Levy B, Ramirez N, et al. Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension. Br J Ophthalmol. 2016;100(3):339–344.
   PubMed Web of Science ®Google Scholar